Page 791«..1020..790791792793..800810..»

Hormone Replacement Therapy (HRT) Market Boosting the Growth Worldwide: Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories – BIZNEWS

Posted: December 31, 2020 at 3:51 pm

This detailed research study of the Hormone Replacement Therapy (HRT) market specializes in facts and figures with the business operation and some suggestive visions in terms of growth prospects of the market. Moreover, the research report brings an in-depth study regarding the segmentation of the global Hormone Replacement Therapy (HRT) market based on the types, product categories, applications, and more.

The study also covers the historical cost concept in the account of major concepts and understanding about how a business entity would perform in the Hormone Replacement Therapy (HRT) market and evaluations in the near future.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @: https://www.contrivedatuminsights.com/request-sample/14443

Top Key Players: Abbott Laboratories

Novartis

Pfizer

Mylan Laboratories

Merck & Co.

Amgen

Novo Nordisk

Bayer

Eli Lily

Wyeth

Genentech.

Also, the research report also covers broad market space, demand, and supply mechanism operating in the market that majorly determines factors behind the growth of the industry. Moreover, the research reports clarify product details and dimensions capable that deliver organizational changes in the operations, promotions, and product distribution strategies that help generate popularity of the Hormone Replacement Therapy (HRT) market across the globe.

This research report significantly covers the complex calculations involved in predicting the outcomes of a business entity in consideration of past and present performances.

Global Hormone Replacement Therapy (HRT) Market Segmentation:

On the Basis of Type:OralParenteralTransdermalOthers

On the Basis of Application:MenopauseHypothyroidismMale HypogonadismGrowth Hormone DeficiencyOthers

Get Special Discount: https://www.contrivedatuminsights.com/request-discount/14443

Regional Outlook

As per the research study by Contrive Datum Insights, the global Hormone Replacement Therapy (HRT) market has fragmented across several regions such as North America, Latin America, Asia-Pacific, Africa, and Europe on the basis of key players. It covers the broad analysis of regional business overview including the financial overview.

Key highlights of this research report:

Overview of the key market segments propelling or hampering the market growth

The cost analysis of the Global Hormone Replacement Therapy (HRT) Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Key questions answered in the report include:

Quick Buy: https://www.contrivedatuminsights.com/buy/14443

Any special requirements about this report, please let us know and we can provide custom report.

See the original post here:
Hormone Replacement Therapy (HRT) Market Boosting the Growth Worldwide: Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories - BIZNEWS

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy (HRT) Market Boosting the Growth Worldwide: Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories – BIZNEWS

New Jefferson Health practice geared toward LGBTQ+ patients opens in Haddonfield – nj.com

Posted: December 31, 2020 at 3:51 pm

Jefferson Health Haddonfield Primary & Specialty Care, a new LGBTQ+ Affirming Practice at 80 Tanner St. in Haddonfield, will begin seeing patients on Monday, Jan. 4.

Accessible by car and public transportation, the practice will provide a safe space for LGBTQ+ patients to seek inclusive, multidisciplinary care.

While focused on caring for LGBTQ patients, the practice will be open to all adult members of the community needing medical care, offering services in infectious diseases care, HIV, behavioral health and primary care.

We will also provide hormone replacement therapy, Medication-Assisted Treatment for opioid use disorder, and pre-exposure prophylaxis for HIV prevention upon opening, said Jefferson Medical Group ambulatory operations vice president Amanda Kimmel. In the future, gynecology services and breast surgery will be available as well.

All staff and providers at the practice will be trained and proficient in LBGTQ+ culturally competent care, Kimmel said.

Our goal is to foster a safe, positive space where the unique and specific health needs of the local LGBTQ+ community are met with compassion and expertise, says Kimmel. Despite existing federal protections, the LGBTQ+ community continues to face significant healthcare discrimination, which often leads to a delay in seeking both preventive care and care for urgent or life-threatening conditions.

Members of the LGBTQ+ community are more likely to experience issues related to mental health and substance use disorder, as well as several chronic conditions, diseases and infections.

As a member of the LGBTQ+ community myself, Ive always found it challenging to find competent healthcare, said medical director Dr. Todd Levin, an infectious diseases specialist. Our patients wont have to worry about stigma and will know that every provider is trained to provide optimal care for them specifically. Here, patients will feel accepted and we can address issues that some providers are not comfortable talking about or treating, like prescribing PrEP for HIV prevention or giving the proper health screenings to transgender patients.

Call 844-542-2273 for more information or to schedule an appointment.

Send community news to south@njadvancemedia.com.

See more here:
New Jefferson Health practice geared toward LGBTQ+ patients opens in Haddonfield - nj.com

Posted in Hormone Replacement Therapy | Comments Off on New Jefferson Health practice geared toward LGBTQ+ patients opens in Haddonfield – nj.com

Is Evofem Biosciences Inc (EVFM) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

The 35 rating InvestorsObserver gives to Evofem Biosciences Inc (EVFM) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 27 percent of stocks in the Biotechnology industry, EVFMs 35 overall rating means the stock scores better than 35 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Evofem Biosciences Inc (EVFM) stock is trading at $2.43 as of 9:45 AM on Monday, Dec 28, an increase of $0.07, or 2.97% from the previous closing price of $2.36. The stock has traded between $2.40 and $2.47 so far today. Volume today is light. So far 155,885 shares have traded compared to average volume of 2,741,457 shares.

Click Here to get the full Stock Score Report on Evofem Biosciences Inc (EVFM) Stock.

Read the original:
Is Evofem Biosciences Inc (EVFM) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Evofem Biosciences Inc (EVFM) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Is Cellectar Biosciences Inc (CLRB) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

Cellectar Biosciences Inc (CLRB) is near the top in its industry group according to InvestorsObserver. CLRB gets an overall rating of 80. That means it scores higher than 80 percent of stocks. Cellectar Biosciences Inc gets a 94 rank in the Biotechnology industry. Biotechnology is number 32 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 80 would rank higher than 80 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Cellectar Biosciences Inc (CLRB) stock is down -2.73% while the S&P 500 has risen 0.7% as of 9:45 AM on Monday, Dec 28. CLRB is lower by -$0.06 from the previous closing price of $2.20 on volume of 160,048 shares. Over the past year the S&P 500 has risen 15.76% while CLRB is lower by -5.31%. CLRB lost -$1.19 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

Go here to see the original:
Is Cellectar Biosciences Inc (CLRB) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Cellectar Biosciences Inc (CLRB) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Should You Buy Voyager Therapeutics Inc (VYGR) in Biotechnology Industry? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

Voyager Therapeutics Inc (VYGR) is around the bottom of the Biotechnology industry according to InvestorsObserver. VYGR received an overall rating of 33, which means that it scores higher than 33 percent of all stocks. Voyager Therapeutics Inc also achieved a score of 22 in the Biotechnology industry, putting it above 22 percent of Biotechnology stocks. Biotechnology is ranked 30 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Voyager Therapeutics Inc (VYGR) stock is lower by -4.86% while the S&P 500 is higher by 0.17% as of 11:15 AM on Thursday, Dec 24. VYGR has fallen -$0.41 from the previous closing price of $8.44 on volume of 324,546 shares. Over the past year the S&P 500 has gained 14.09% while VYGR has fallen -43.41%. VYGR earned $1.04 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 7.72.

Click Here to get the full Stock Score Report on Voyager Therapeutics Inc (VYGR) Stock.

View post:
Should You Buy Voyager Therapeutics Inc (VYGR) in Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Should You Buy Voyager Therapeutics Inc (VYGR) in Biotechnology Industry? – InvestorsObserver

Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

The 66 rating InvestorsObserver gives to Allakos Inc (ALLK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, ALLKs 66 overall rating means the stock scores better than 66 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Allakos Inc (ALLK) stock has risen 0.58% while the S&P 500 has fallen -0.22% as of 3:25 PM on Tuesday, Dec 22. ALLK is higher by $0.84 from the previous closing price of $144.00 on volume of 295,894 shares. Over the past year the S&P 500 is up 14.35% while ALLK is higher by 41.36%. ALLK lost -$2.74 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Allakos Inc (ALLK) Stock.

Visit link:
Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? – InvestorsObserver

Is Aquestive Therapeutics Inc (AQST) The Right Choice in Biotechnology? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

The 53 rating InvestorsObserver gives to Aquestive Therapeutics Inc (AQST) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 62 percent of stocks in the Biotechnology industry, AQSTs 53 overall rating means the stock scores better than 53 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Aquestive Therapeutics Inc (AQST) stock has fallen -5.9% while the S&P 500 has risen 0.17% as of 11:15 AM on Thursday, Dec 24. AQST has fallen -$0.39 from the previous closing price of $6.68 on volume of 289,118 shares. Over the past year the S&P 500 has risen 14.09% while AQST has risen 3.11%. AQST lost -$1.53 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aquestive Therapeutics Inc (AQST) Stock.

See more here:
Is Aquestive Therapeutics Inc (AQST) The Right Choice in Biotechnology? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Aquestive Therapeutics Inc (AQST) The Right Choice in Biotechnology? – InvestorsObserver

Is Stoke Therapeutics Inc (STOK) a Winner in the Biotechnology Industry? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

The 65 rating InvestorsObserver gives to Stoke Therapeutics Inc (STOK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 79 percent of stocks in the Biotechnology industry, STOKs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Stoke Therapeutics Inc (STOK) stock is down -0.64% while the S&P 500 has risen 0.53% as of 2:32 PM on Wednesday, Dec 23. STOK has fallen -$0.38 from the previous closing price of $59.92 on volume of 143,445 shares. Over the past year the S&P 500 has gained 14.99% while STOK has risen 108.18%. STOK lost -$1.47 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Stoke Therapeutics Inc (STOK) Stock.

Original post:
Is Stoke Therapeutics Inc (STOK) a Winner in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Stoke Therapeutics Inc (STOK) a Winner in the Biotechnology Industry? – InvestorsObserver

Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

A rating of 12 puts AIM ImmunoTech Inc (AIM) near the bottom of the Biotechnology industry according to InvestorsObserver. AIM ImmunoTech Inc's score of 12 means it scores higher than 12% of stocks in the industry. AIM ImmunoTech Inc also received an overall rating of 20, putting it above 20% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 20 would rank higher than 20 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

AIM ImmunoTech Inc (AIM) stock is lower by -2.91% while the S&P 500 has gained 0.39% as of 10:43 AM on Wednesday, Dec 23. AIM is down -$0.06 from the previous closing price of $2.06 on volume of 958,792 shares. Over the past year the S&P 500 has gained 14.83% while AIM has gained 308.16%. AIM lost -$0.44 per share the over the last 12 months.

Click Here to get the full Stock Score Report on AIM ImmunoTech Inc (AIM) Stock.

Read more:
Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? – InvestorsObserver

Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted: December 29, 2020 at 4:56 am

A rating of 96 puts Anavex Life Sciences Corp (AVXL) near the top of the Biotechnology industry according to InvestorsObserver. Anavex Life Sciences Corp's score of 96 means it scores higher than 96% of stocks in the industry. Anavex Life Sciences Corp also received an overall rating of 86, putting it above 86% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Anavex Life Sciences Corp (AVXL) stock is down -2.26% while the S&P 500 is up 0.9% as of 10:41 AM on Monday, Dec 28. AVXL is lower by -$0.13 from the previous closing price of $5.75 on volume of 344,926 shares. Over the past year the S&P 500 is higher by 15.99% while AVXL is up 138.14%. AVXL lost -$0.43 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Anavex Life Sciences Corp (AVXL) Stock.

Read the original here:
Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? – InvestorsObserver

Page 791«..1020..790791792793..800810..»